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Introduction: Mutations in the TNFRSF1A gene, encoding tumor necrosis factor receptor 1 (TNF-R1), are associated
with the autosomal dominant autoinflammatory disorder, called TNF receptor associated periodic syndrome
(TRAPS). TRAPS is clinically characterized by recurrent episodes of long-lasting fever and systemic inflammation. A
novel mutation (c.262 T > C; S59P) in the TNFRSF1A gene at residue 88 of the mature protein was recently identified
in our laboratory in an adult TRAPS patient. The aim of this study was to functionally characterize this novel
TNFRSF1A mutation evaluating its effects on the TNF-R1-associated signaling pathways, firstly NF-κB, under particular
conditions and comparing the results with suitable control mutations.
Methods: HEK-293 cell line was transfected with pCMV6-AC construct expressing wild-type (WT) or c.262 T > C
(S59P), c.362G > A (R92Q), c.236C > T (T50M) TNFRSF1A mutants. Peripheral blood mononuclear cells (PBMCs) were
instead isolated from two TRAPS patients carrying S59P and R92Q mutations and from five healthy subjects. Both
transfected HEK-293 and PBMCs were stimulated with tumor necrosis factor (TNF) or interleukin 1β (IL-1β) to evaluate
the expression of TNF-R1, the activation of TNF-R1-associated downstream pathways and the pro-inflammatory
cytokines by means of immunofluorescent assay, array-based technique, immunoblotting and immunometric
assay, respectively.
Results: TNF induced cytoplasmic accumulation of TNF-R1 in all mutant cells. Furthermore, all mutants presented
a particular set of active TNF-R1 downstream pathways. S59P constitutively activated IL-1β, MAPK and SRC/JAK/
STAT3 pathways and inhibited apoptosis. Also, NF-κB pathway involvement was demonstrated in vitro by the
enhancement of p-IκB-α and p65 nuclear subunit of NF-κB expression in all mutants in the presence of TNF or
IL-1β stimulation. These in vitro results correlated with patients’ data from PBMCs. Concerning the pro-inflammatory
cytokines secretion, mainly IL-1β induced a significant and persistent enhancement of IL-6 and IL-8 in PBMCs carrying
the S59P mutation.
Conclusions: The novel S59P mutation leads to defective cellular trafficking and to constitutive activation of TNF-R1.
This mutation also determines constitutive activation of the IL-1R pathway, inhibition of apoptosis and enhanced and
persistent NF-κB activation and cytokine secretion in response to IL-1β stimulation.* Correspondence: eliana.greco@unipd.it
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Tumor necrosis factor receptor-associated periodic syn-
drome (TRAPS; OMIM 142680) is the second most com-
mon inherited autosomal dominant autoinflammatory
disease [1]. It is caused by mutations in the TNFRSF1A
gene located on chromosome 12p13 and encodes the
55 kDa receptor for tumor necrosis factor receptor 1
(TNF-R1). The disease is clinically characterized by peri-
odic fever, abdominal pain, skin lesions, conjunctivitis,
myalgia and pericarditis. Disease onset generally occurs in
early childhood but it can present in adults, and inflam-
matory attacks can last several weeks. The most severe
complication is AA-type serum amyloidosis, which can
lead to renal impairment and failure [2-4].
The TNF-R1 presents an extracellular domain involved
in ligand binding, a transmembrane domain involved in
receptor solubilization and an intracellular region where
death domains (DD) are involved in signal transduction
[5,6]. The binding of TNF to TNF-R1 causes recruitment
of several intracellular adaptor proteins leading to down-
stream signaling events that activate the inflammatory
(complex I) and apoptotic (complex II) processes. Com-
plex I activation prevails and leads to NF-κB activation
and transcription of anti-apoptotic and pro-inflammatory
genes [7-27].
Almost all known mutations associated with TRAPS
are characterized by the replacement of amino acids in the
extracellular domain of the TNF-R1. More than 100 muta-
tions are registered in the INFEVERS database [18], which
are discerned in high-penetrance and low-penetrance mu-
tations. The former affects mainly the cysteine residues in
the extracellular cysteine-rich domains (CRDs) involved in
disulfide bond formation and extracellular TNF-R1 fold-
ing and function. These mutations are associated with the
most severe clinical phenotype, in which there is high risk
of AA-type serum amyloidosis. Low-penetrance mutations
include genetic variants that introduce or remove pro-
line residues (such as P46L, L57P, S86P, and R92P) or
affect hydrogen bond stabilization of the receptor (such
as T50M) [19]. These mutations affect the secondary
structure of TNF-R1 and are associated with a typical
TRAPS phenotype, but in these cases the risk of AA-type
serum amyloidosis is low [20-22]. Other low-penetrance
TNFRSF1A variations, such as R92Q, are associated with
milder clinical manifestations, suggesting that in these
cases other genetic and/or environmental factors can play
a role in the disease’s pathogenesis [20-26]. The high pene-
trance TNFRSF1A mutations involving the cysteine resi-
dues (C29F, C30R/S, C33G/Y, Y38C, C52F, C55S, C70R/Y,
and C88R/Y) are less frequent (34%) than those with a low
penetrance (76%), the latter being mainly represented by
the T50M (15.8%) and R92Q (28.9%) variants [21].
We recently identified a novel mutation in the
TNFRSF1A gene (exon 3, c.262 T > C) in an adult TRAPSpatient. Clinically, the patient had fever, leukocytosis, re-
current bronchopneumonia, palpebral ptosis, episodes of
arthralgia, myalgia and intermittent erythematosus skin le-
sions of the limbs and trunk. His serum immunoglobulin
D (IgD), immunoglobulin A (IgA) and serum amyloid A
protein (SAA) levels were elevated. While traditional ther-
apy with the TNF inhibitor etanercept was unsuccessful in
this patient, alternative therapy with the interleukin-1 re-
ceptor antagonist (IL-1Ra) anakinra promptly induced dis-
ease remission. The identified new genetic variant results
in a proline for serine amino acid substitution (S59P or
p.Ser88Pro) at residue 88, localized in the extracellular do-
main of the mature protein. This variant might be in-
cluded in the above-described category of mutations that
introduce proline residues. The distinctive cyclic structure
of proline’s side chain gives it an exceptional conform-
ational rigidity, interfering in peptide bond formation with
other amino acids and affecting the secondary structure of
the protein [27].
Overall, the molecular pathogenesis of TRAPS is not
yet completely understood. The change in secondary
structure might cause defective TNF-R1 trafficking, al-
tered ligand binding affinity, reduced activation-induced
shedding and impaired cell signaling. Based on these
premises, several hypotheses have been formulated: the
shedding hypothesis [1,28,29], the misfolding hypothesis
[30-33], the NF-κB hypothesis [34,35] and the recent
ROS hypothesis [36,37].
Since the patient carrying the S59P mutation was re-
sponsive to IL-1Ra but not to anti-TNF therapy, the aim
of this study was to verify whether this mutation modi-
fies the cell signaling, in particular in the NF-κB path-
way, after TNF and IL-1β stimulation.Methods
Wild-type and mutant TNFRSF1A cDNA vectors
We purchased the vector pCMV6-AC (OriGene Tech-
nologies, Inc. Rockville, MD, USA) containing wild-type
(WT) TNFRSF1A cDNA ready for transfection. Three
new constructs containing three mutant TNFRSF1A -
cDNA (c.262 T > C (S59P); c.362G > A (R92Q) and
c.236C > T (T50M)) were obtained using site-direct mu-
tagenesis, and the following mutagenic primers were
used: TNFRFS59P: 5′AGTGTGAGAGCGGCCCCTTC




All the products were sequenced along the full length of
the TNFRSF1A coding region to ensure that only the de-
sired mutations were introduced. Plasmid isolation from
bacterial culture was carried out using the PureYield Plas-
mid Maxiprep System (Promega, Milano, Italy).
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Human embryonic kidney (HEK-293) cell line was used
for the transfection. This cell line expressed moderate
levels of endogenous TNF receptors and exhibited high
transfection efficiency. A total of 4 μg of plasmid were in-
cubated with 10 μL Lipofectamine™ 2000 (Invitrogen, San
Giuliano Milanese, Italy) in 500 μL serum and antibiotic-
free DMEM (Invitrogen, San Giuliano Milanese, Italy) for
20 minutes at 25°C. The reagent was then directly added
to each cell culture well (200,000 cells) in a 6-well plate
format. After 6 hours, media were replaced with fresh
serum-supplemented media, and the cells were main-
tained at 37°C for the subsequent 24 hours. To obtain
stable transformed cells, they were treated with 0.8 mg/
mL Geneticin® (G418) (Invitrogen, San Giuliano Milanese,
Italy) for 15 days.
Patients
Two TRAPS patients were referred to the Rheumatology
Unit of University of Padova and were studied: one
carrying the S59P mutation and the other the R92Q mu-
tation. Moreover, 5 subjects (3 males and 2 females, age
range: 30 to 50 years) without any variants in the
TNFRSF1A gene were studied as healthy controls. At the
time the study was carried out, the TRAPS patients were
on anakinra and infliximab therapy, respectively, and did
not present inflammatory symptoms. The study protocol
was approved by our institutional review board (Comi-
tato Etico per la Sperimentazione, Azienda Ospedaliera
di Padova, protocol number: 0060237) and the patients
gave their fully informed written consent to participate
in the study. The clinical characteristics of the enrolled
TRAPS patients are detailed in Table 1.
According to our medical file, which includes 300 Italian
patients with a clinical suspect of TRAPS, none carried
the T50M mutation.
TNFRSF1A mutation detection
Genomic DNA was extracted from whole blood using
the standard method (MagNA Pure System, Roche S.p.A.,
Monza, Italy). After amplification by polymerase chain re-
action with primers as described by D’Osualdo et al. [38],
sequencing of the TNFRSF1A gene was performed using
the automatic sequencer 3130ABI PRISM Genetic Analyzer
(Applied Biosystems, CA, USA). Chromatograms were an-
alyzed with Chromas Lite 2.01 software (Technelysium
Pty Ltd., South Brisbane, QLD, Australia).
Peripheral blood mononuclear cells isolation and culture
Blood (20 mL) was collected with EDTA K3 test tubes and
was processed within 2 hours of sampling to isolate mono-
nuclear cells by gradient centrifugation (Histopaque®-1077,
Sigma-Aldrich, Milano, Italy). Peripheral blood mono-
nuclear cells (PBMCs) were suspended in culture medium(Roswell Park Memorial Institute Medium (RPMI) supple-
mented with 0.1% gentamicin, 10% FCS and 1% glutamine;
Invitrogen, San Giuliano Milanese, Italy) and incubated
at 37°C for 24 and 72 hours prior to experimental
manipulation to prevent any experimental anomalies
arising as a consequence of therapy.
Immunofluorescence
HEK-293 transfected with WT or mutant TNFRSF1A
were seeded onto slides (3 × 105) and maintained in cul-
ture for 24 hours. Cells were stimulated with or without
TNF (60 ng/mL) (Sigma-Aldrich, Milano, Italy) for 1 hour
to induce TNF receptor expression. They were then
washed in PBS 1X and fixed in 4% formaldehyde fixative
(Sigma-Aldrich, Milano, Italy) for 10 minutes at room
temperature.
Dual indirect staining was performed using primary
monoclonal mouse antibody anti-human CRI/TNF-R1-PE
(R&D Systems Inc.) Minneapolis, Minnesota, USA and
the appropriate Alexa Fluor 488-conjugated secondary
antibody (Invitrogen, San Giuliano Milanese, Italy). The
cells were washed in PBS 1X, incubated with NH4Cl
(50 mM) for 10 minutes and with Triton X-100 (0.1%) for
5 minutes. The cells were then washed in PBS 1X and incu-
bated with PBS with BSA (1%) for 45 minutes. The first pri-
mary antibody was added to the cells and incubated for one
hour at room temperature in the dark. Cells were then
washed three to four times in PBS 1X. The secondary anti-
body was added to the cells and incubated for one hour at
room temperature in the dark. Confocal microscopy was
performed using a Radiance 2000 confocal laser scanning
microscope (Bio-Rad Laboratories Inc., Milano, Italy).
Reverse phase protein array analysis
Reverse phase protein array (RPPA) analysis was per-
formed using a procedure previously optimized and vali-
dated [39]. Briefly, cell lysates were solubilized in 4×
SDS loading buffer (Sigma-Aldrich, Milano, Italy) and
heated for 5 minutes at 95°C. Samples were spotted in
duplicate onto nitrocellulose-coated glass slides (Grace
Bio-labs Bend, Oregon, USA) using a microarraying
robot (MicroGrid 610, Digilab, Marlborough, MA,
USA). The printed slides were blocked and incubated
overnight at 4°C with shaking with the specific primary
antibodies (Cell Signaling Technology, Danvers, MA,
USA). Additional file 1 shows in more detail the list of
primary antibodies used for RPPA analysis with their re-
spective signaling pathways. β-actin was included as a
housekeeping protein to control protein loading. After
incubation with infrared secondary antibodies (800 CW
LI-COR anti-rabbit antibody and 700 CW LI-COR anti-
mouse antibody) Lincoln, Nebraska, USA, the slides
were scanned with a Licor Odyssey scanner (LI-COR,
Biosciences Lincoln, Nebraska, USA) at 21 μm resolution
Table 1 Clinical characteristics of the two TRAPS patients included in the study
TRAPS patients
TNFRSF1A variants S59P R92Q
Ethnicity/gender Italian/Male Italian/Female
Age at onset (year) 49 years (1991) 41 (2007)
Age at TRAPS diagnosis (year) 67 years (2009) 45 (2011)
Age at enrolment (year) 71 years (2013) 46 (2012)
Clinical manifestations at onset Episodes of recurrent bronchopneumonia, fever,
leukocytosis, refractory iron-deficiency anaemia,
myalgia, intermittent erythematosus skin lesions
on limbs and trunk and one episode
of pericarditis.
Episodes of fever, myalgia, arthritis,
headache and episcleritis.
Frequency of attacks (number per year) 4 6
Duration of the attacks (days) 7-14 7-14
Amyloid deposits Yes (Spleen; 1996) No
Haematological and biochemical indices at diagnosis during an attack
Polymorphonuclear cells 24,190/μL 3,790/μL
Haemoglobin 10 g/L 12 g/L
Platelet count 842,000/μL 283,000/μL
Proteinuria Absent Absent
C-reactive protein 234 mg/L 20 mg/L
Serum amyloid A protein 1270 mg/L 59 mg/L
Serum IgD 271 g/L 44 g/L
Serum IgA 5.03 g/L 3.7 g/L
Erythrocyte sedimentation rate 120 mm/h 44 mm/h
Acute phase response Persistent Intermittent
Treatment Prednisone 25 mg/day (1992–2008) Sulfasalazine 2 g/day (since 2010)
Prednisone 7.5 mg/day (2008–2011) Infliximab 6 mg/kg once per month
(2012–2014)
Etanercept 25 mg twice per week (2011–2012) Methotrexate 15 mg/week (since 2013)
Anakinra 100 mg/day (since 2012) Etanercept 25 mg twice per week
(since 2014)
Response to treatment Partial to prednisone Partial
Unresponsive to etanercept
Complete to anakinra
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with GenePix Pro-6 Microarray Image Analysis software
(Molecular Services Inc. Sunnyvale, California, USA). Pro-
tein signals were determined with background subtraction
and normalization to the internal housekeeping targets
using an Reverse-phase protein analyzer [40].
Immunoblotting
WT or mutant TNFRSF1A HEK-293 and PBMCs were
seeded (5 × 106) onto Petri dishes (diameter: 10 cm) and
maintained in a laboratory culture for 24 hours. Cells
were incubated with and without TNF (6 ng/mL) or with
IL-1β (1 ng/mL) (Sigma-Aldrich, Milano, Italy) for 10 mi-
nutes to activate signaling pathways. Following stimula-
tion, the Petri dishes were immediately transferred to anice bath, and the cells were washed twice with cold PBS,
resuspended in 100 μL of cold lysis buffer (20 mM Tris–
HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% Triton X-
100, 50 mM NaF, 10 mM Na4P2O7, 1 mM Na3VO4, and
10% protease inhibitor cocktail (Sigma-Aldrich, Milano,
Italy)). Lysates were centrifuged for 10 minutes at
14,000 rpm at 4°C and the supernatants were collected.
The pellets were resuspended in a nuclear extraction
buffer mix (Thermo Scientific Inc., Rockford, USA) and
proceeded to generate nuclear extracts, as described in
the manufacturer’s instructions. Total cytosolic and nu-
clear proteins were measured using the Bio-Rad Protein
Assay Kit (Bio-Rad Laboratories, Milano, Italy).
For each sample, 40 μg proteins were electrophoresed
using a 4-12% NuPAGE® Novex Bis-Tris SDS-PAGE Gel
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(Invitrogen Life Technologies, Monza, Italy), and were
electrophoretically transferred to nitrocellulose membrane
(iBlot® Transfer Stack, Invitrogen Life Technologies,
Monza, Italy) using iBlot® Dry Blotting System (Invitrogen
Life Technologies, Monza, Italy). The membranes were in-
cubated for 1 hour in blocking buffer (5% low-fat powder
milk resuspended in PBS-T (PBS with 0.1% Tween-20)).
They were then incubated overnight with the primary
antibodies (anti-phospho IkB-α (Ser32) and anti-phospho-
NF-κB subunit p65 (Ser536) (Cell Signaling Technology,
Danvers, MA) and anti-β-actin (Sigma-Aldrich, Milano,
Italy)) diluted 1:5,000 (β-actin) or 1:3,000 (all the others)
in blocking buffer. The blots were washed three times in
PBS-T for 15 minutes and incubated for 1 hour with alka-
line phosphatase-conjugated anti-rabbit or anti-mouse
secondary antibodies (Cell Signaling Technology, Danvers,
MA, USA). The blots were washed three times in PBS-T
for 15 minutes and developed with the ECL Advance
Western Blot Detection Kit (GE Healthcare Technologies,
Milano, Italy).
Cytokine assay
Cells transfected with WT or mutant TNFRSF1A and
PBMCs cultured for 24 and 72 hours were incubated at
200 × 103/mL in 24-well plates in culture medium. The
cells were stimulated with and without TNF (6 ng/mL)
or IL-1β (1 ng/mL) or lipopolysaccharide ((LPS) 1 μg/mL)
as positive controls (PC) for four hours. Supernatants
were collected, centrifuged to remove cells and debris and
stored at −80°C. IL-1β, IL-6, IL-8 and TNF cytokine
analysis was performed using an immunometric assay
(IMMULITE-Siemens, Milano, Italy).
Statistical analysis
Two sets of data were analyzed using an independent
sample t test. The data of more than two groups were
analyzed using one-way analysis of variance (ANOVA)
and Bonferroni’s test for pairwise comparisons. The stat-
istical software Package for the Social Sciences (SPSS
version 9) was used. All experimental data were obtained
from a series of independent experiments (n = 3).
Results
S59P is a novel TRAPS-associated mutation
Based on the clinical suspect of TRAPS, a 67-year-old
Italian male (clinical characteristics detailed in Table 1)
was sent to our department. By performing TNFRSF1A
sequencing, this patient was demonstrated to carry in het-
erozygosis a mutation which has never been previously
described (Figure 1, panel A). This single-base mutation
(c.262 T > C), located in exon 3, results in a proline for
serine amino acid substitution (S59P) at residue 88 of
the mature protein. We studied another TRAPS patient(clinical characteristics also detailed in Table 1) who
carried in heterozygosis the common single-base muta-
tion (c.362G > A) in exon 4 (Figure 1, panel B), resulting
in an arginine for glutamine amino acid substitution
(R92Q) at residue 121 of the mature protein.
Different TNFRSF1A mutants activate specific TNF-R1
downstream signaling pathways
To ascertain whether the novel S59P mutation is causative
of an altered TNF-R1 expression and function, in vitro
experiments were performed using the HEK-293 cell line
transfected with a plasmid expression vector carrying
the S59P-mutated TNFRSF1A. For comparison, the same
HEK-293 cells were transfected with the WT TNFRSF1A
and the R92Q and T50M TNFRSF1A mutants.
We first analyzed by indirect immunofluorescence TNF-
R1 expression in unstimulated (Figure 2, left panels) and
TNF-stimulated (Figure 2, right panels) WT, S59P, R92Q
and T50M HEK-293 transfected cells. In unstimulated
WT cells (Figure 2A), the TNF-R1 was weakly expressed
in the cytosol. A similar pattern was observed in S59P
(Figure 2B) and R92Q (Figure 2C) HEK-293 mutant cells,
while in the presence of T50M mutation a more intense
cytosolic fluorescence with a granular-type pattern could
be identified (Figure 2D). TNF at the dosage of 60 ng/mL
caused an enhanced expression and granularity of cyto-
solic TNF-R1 not only in WT (Figure 2A1), but also in all
mutant HEK-293 cells. Although a clear differentiation of
cell surface from intracellular localizations was not pos-
sible, an enforced fluorescence with granular pattern out-
lining cell shape was observed in all TNF-stimulated cells.
We then verified whether the TNFRSF1A mutations
are associated with a constitutive activation of the TNF-
R1 or other signaling pathways, and whether these mu-
tations modify intracellular signaling in response to TNF
and IL-1β, taking into account that the patient carrying
the S59P mutation had a complete clinical response
when treated with IL-1Ra but not with anti-TNF therapy.
RPPA with unstimulated and TNF- or IL-1β-stimulated
cells were performed and the following pathways analyzed:
TNF-R1, MAP kinase, c-Jun, IL-1β, NF-κB, ERK, inflam-
masome, PI3/AKT, SRC/JAK/STAT and apoptosis. In
Figure 3 the percentage changes in fluorescence inten-
sity relative to untreated WT HEK-293 cells are shown;
for any studied signaling pathway, a key component
molecule is shown. Additional file 2 shows in more de-
tail all remaining RPPA data for any studied signaling
pathway. A constitutive activation of the TNF-R1 and
inflammasome signaling pathways, characterized by in-
creased A20/TNFAIP3, p-NF-κB and caspase 1, was
associated with the T50M, not with the S59P or R92Q mu-
tations. The newly identified S59P mutation was associated
with the constitutive activation of IL-1β (pIRAK), MAPK
(p38MAPK) and SRC/JAK/STAT3 (SOCS3) pathways. In
Figure 1 DNA sequence electropherograms of TNFRSF1A. A: electropherogram of the heterozygous single-base mutation (c.262 T > C) in exon 3,
resulting in a Pro for Ser amino acid substitution. B: electropherogram of the heterozygous single-base mutation (c.362G > A) in exon 4, resulting
in an Arg for Gln amino acid substitution.
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STAT3 was associated with the inhibition of PI3K/AKT,
ERK, c-Jun and inflammasome pathways. Apoptosis
(BCL-2) was constitutively inhibited in all mutants.
TNF and IL-1β activated the TNF receptor pathway and
inhibited apoptosis in WT cells. The TNF-R1 pathway
was not activated by TNF or IL-1β in mutant cells, nor
was it even inhibited by IL-1β in the T50M mutant. Dif-
ferently from the R92Q and T50M mutants, the S59P
mutation did not abolish the anti-apoptotic effects of
TNF and IL-1β.
TNFRSF1A mutants activate NF-κB pathway in transfected
cells and in peripheral blood mononuclear cells
We then ascertained in more depth whether a different
response to TNF and IL-1β in terms of activation or in-
hibition of the NF-κB pathway, depends on TNFRSF1A
mutations. This objective took into consideration that
NF-κB is one of the main TNF-R1 downstream signaling
pathways [41], and that both pathways were differently
affected by S59P, R92Q and T50M mutations (shown in
RPPA results). The effects of TNF and IL-1β on two key
NF-κB signaling molecules, p-IκB-α (Ser32) and p65 com-
ponent (p-NF-κB (Ser536)), were assessed by Western blot
analysis in WT, S59P, R92Q and T50M HEK-293, and in
PBMCs obtained from TRAPS patients and controls.
Figure 4 shows Western blot results of transfected
HEK-293 cell lines. TNF and IL-1β reduced the phos-
phorylation of IκB-α (p-IκB-α Ser32) in WT cells, while
the opposite was found when they were added to S59P
and T50M mutant cells. In R92Q cells, little if any vari-
ation in IκB-α phosphorylation was seen. The Western
blot analysis of the p65 component in isolated nuclei (p-
NF-κB Ser536) showed that TNF and IL-1β did not activate
p65 in WT HEK-293 cells. By contrast, this component
was phosphorylated by TNF in all mutants, and by IL-1βin S59P and R92Q, but not T50M mutants. Confirming
RPPA findings, p65 was constitutively activated in the
T50M HEK-293, and this activation was sustained by TNF
and partly counteracted by IL-1β.
Figure 5 shows Western blot analysis of p-IκB-α (p-IκB-α
Ser32) and of nuclear p65 component (p-NF-κB Ser536) in
control and TRAPS PBMCs kept in culture for 24 hours
unstimulated or stimulated with TNF and IL-1β. In basal
conditions IκB-α phosphorylation was higher in TRAPS
with respect to control PBMCs. In both control and
TRAPS patients TNF reduced IκB-α phosphorylation. IL-
1b reduced the phosphorylation of IkB-a in control
PBMCs, while enhnacing it in TRAPS PBMCs. In the
same experimental conditions, p65 activity in isolated nu-
clei was constitutively elevated only in S59P TRAPS
PBMCs. Both TNF and IL-1β induced the p65 phosphor-
ylation in controls and TRAPS PBMCs.
TNFRSF1A mutants increase pro-inflammatory cytokine
secretion in transfected cells and peripheral blood
mononuclear cells
We then examined if NF-κB activation might be func-
tionally linked to the secretion of inflammatory cyto-
kines. Levels of IL-8 were measured in WT, S59P, R92Q
and T50M HEK-293 supernatants. Levels of IL-1β, IL-6,
IL-8 and TNF were measured in PBMCs supernatants.
Cells were incubated in fresh media with or without
TNF (6 ng/mL), IL-1β (1 ng/mL) or LPS (1 μg/mL) as a
positive control for 4 hours.
Non-stimulated S59P, R92Q and T50M HEK-293
released higher levels of IL-8 compared to WT cells
(t = −29, P <0.0001; t = −89.2, P <0.0001; t = −8.6, P <0.001)
(Figure 6). TNF induced a significantly higher IL-8 se-
cretion in S59P (t = −5.1, P <0.005) and R92Q (t = −52.3,
P <0.0001), not in T50M (t = −0.8; p: not significant)
mutants, with respect to WT HEK-293 cells.
Figure 2 TNF-R1 expression in cell lines. Confocal microscopy analysis of anti-TNF-R1 (green) immunofluorescent staining. HEK-293 cells
transfected with wild-type (WT) or mutant TNFRSF1A remained unstimulated or they were stimulated with 60 ng/mL TNF. Panel A (without TNF)
and A1 (with TNF) are WT TNFRSF1A HEK-293. Panel B (without TNF) and B1 (with TNF) are S59P TNFRSF1A HEK-293. Panel C (without TNF) and
C1 (with TNF) are R92Q TNFRSF1A HEK-293. Panel D (without TNF) and D1 (with TNF) are T50M TNFRSF1A HEK-293.
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ture of LPS induced significantly higher IL-1β (control:
F = 35, P <0.0001; S59P: F = 31, P <0.0001; R92Q: F =
153, P <0.0001), IL-6 (control: F = 44, P <0.0001; S59P:
F = 4,046, P <0.0001; R92Q: F = 661, P <0.0001), IL-8
(control: F = 45, P <0.0001; S59P: F = 808, P <0.0001;
R92Q: F = 5,755, P <0.0001) and TNF (control: F = 198,
P <0.0001; S59P: F = 448, P <0.0001; R92Q: F = 53,
P <0.0001) secretion. Both TNF and IL-1β inducedsignificantly higher IL-8 release in the control with
respect to the TRAPS PBMCs (TNF: F = 29, P <0.0001;
IL-1β: F = 15, P <0.0001).
In a 72-hour culture (Figure 7, lower panels), LPS no
longer affected IL-1β secretion in control PBMCs, but it
continued to induce IL-1β secretion in the S59P (F =
7.55, P = 0.012) and R92Q (F = 20.8, P <0.0001) TRAPS
PBMCs. LPS maintained its stimulatory effect at 72 hours
on IL-6 (control: F = 179, P <0.0001; S59P: F = 1055,
Figure 3 Reverse phase protein array (RPPA) results. In each panel the percentage changes in fluorescence intensity relative to untreated wild-type
(WT) HEK-293 cells are shown. For any signaling pathway, a key component molecule is shown. Bonferroni’s test for pairwise comparisons: *P <0.05
with respect to untreated WT HEK-293 cells; #P <0.05 with respect to its own untreated control.
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Figure 4 Effects of TNF and IL-1β on the NF-κB pathway in cell lines. Wild-type (WT) and mutant TNFRSF1A HEK-293 unstimulated (NC) or
stimulated for 10 minutes or with TNF (6 ng/mL) or IL-1β (1 ng/mL). Western blot shows p-IκBα (Ser32) and p65 subunit of NF-κB (Ser536) and the
corresponding β-actin, used as a control. The histograms show semi-quantification of band intensities after normalization against the negative
control (100%) (OD; Image J software, version 1.47 NIH, Bethesda, Maryland, USA). Columns indicate percent values.
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224, P <0.0001; S59P: F = 167, P <0.0001; R92Q: F =
1042, P <0.0001) and TNF (control: F = 323, P <0.0001;
S59P: F = 507, P <0.0001; R92Q: F = 466, P <0.0001) se-
cretion. TNF-stimulated IL-8 secretion was significantly
higher in the S59P and R92Q TRAPS than in the control
PBMCs (F = 24, P <0.0001). IL-1β stimulus maintained
both IL-6 and IL-8 secretion higher in the S59P and R92Q
TRAPS than in the control PBMCs (F = 11, P <0.005;
F = 322, P <0.0001) (Figure 7, lower panels).
Discussion
Mutations in the TNFRSF1A gene cause the autosomal-
dominant, with incomplete penetrance, autoinflamma-
tory disorder TRAPS. Mutations located in the CRDs
region of the receptor are highly penetrant and associ-
ated with the most severe clinical phenotypes. However,these mutations are less frequent than those involving
extracellular non-cysteine residues, with R92Q and T50M
being the most common [1]. The cellular mechanisms
underlying the pathophysiology of TRAPS are complex
and depend on the mutation involved, which then defines
some of its clinical features [21,42].
We identified a novel TNFRSF1A mutation in an adult
patient diagnosed as having TRAPS. This patient had a
variety of clinical manifestations, some of which were
commonly associated with TRAPS (recurrent episodes of
fever, myalgia and erythematosus skin lesions), and others
which are reported less frequently (pericarditis and pneu-
monia) [43]. Sequencing of the TNFRSF1A gene was per-
formed in this patient after about 18 years of recurrent
episodes of bronchopneumonia, fever and other systemic
signs of inflammation with an incomplete response to
steroid treatment. This long lag time between disease
Figure 5 NF-κB pathway in peripheral blood mononuclear cells. Control (wild-type (WT)) and TRAPS peripheral blood mononuclear cells
unstimulated or stimulated for 10 minutes with TNF (6 ng/mL) or IL-1β (1 ng/mL). Western blot shows p-IκBα (Ser32) and p65 subunit of NF-κB
(Ser536) and the corresponding β-actin, used as control. The histograms show semi-quantification of band intensities after normalization against
the negative control (100%) (OD; Image J software, version 1.47 NIH, Bethesda, Maryland, USA). Columns indicate percent values.
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disease onset and TRAPS first description [1]. The iden-
tified novel mutation was located in exon 3 and leads to
the substitution of proline for serine at residue 88 of
TNF-R1 (S59P).Figure 6 Proinflammatory cytokine response in cell lines. IL-8 levels
in wild-type (WT) and mutant TNFRSF1A HEK-293 unstimulated
(white columns) or stimulated (black columns) for 4 hours at 37°C
with TNF (6 ng/mL). Data displayed as mean ± SEM. *P <0.005;
**P <0.001; ***P <0.0001 respect to WT.Any amino acid substitution in the ectodomain of
TNF-R1 might affect its physiology, including membra-
nal expression levels, three-dimensional receptor folding
and stimulus-dependent or independent activation. The
novel S59P mutation determines the presence in the
TNF-R1 of one more proline residue, which might inter-
fere with three-dimensional receptor folding, since the
distinctive cyclic structure of proline’s side chain gives it
an exceptional conformational rigidity and might cause a
bend in the receptor’s secondary amino acid structure
[27]. These structural consequences might subsequently
cause an aberrant behaviour of the receptor, including
ligand independent gain-of-function, which underlies
TRAPS pathophysiology.
To understand the functional features of this novel
S59P mutation, we set out to compare it with two fre-
quent mutations that are well known in the literature:
the R92Q and T50M mutations [20-23,31-33,38,44,45].
These two mutations were chosen in view of several con-
siderations: neither involves cysteine residues, the R92Q
mutation is associated with a variable phenotype [23], and
the T50M mutation is associated with a typical TRAPS
phenotype [21].
As it is difficult to study the pathophysiologic mecha-
nisms of TRAPS in the patients themselves, we employed
Figure 7 Proinflammatory cytokine response in peripheral blood mononuclear cells. Cytokine levels (IL-1β, IL-6, IL-8 and TNF) in control (WW)
and TRAPS peripheral blood mononuclear cells maintained in culture for 24 (panel A) and 72 hours (panel B) and unstimulated or stimulated for
4 hours with LPS (1 μg/mL) (positive control), TNF (6 ng/mL) or IL-1β (1 ng/mL). Columns represent mean values ± SEM. *P <0.0001; °P <0.05;
°°P <0.001 with respect to WW.
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examined using the patients’ cells. We first focused on the
expression of TNF-R1 by immunofluorescence and found
that this receptor is homogeneously distributed in the
cytosol of WT cells. S59P and R92Q mutations did not
significantly modify this pattern, while T50M caused an
enhanced cytosolic TNF-R1 expression with a granular
appearance. These results are supported by previous data
from Rebelo et al. [32], who showed by flow cytometry
that the WT and R92Q TNF-R1 have a significant cellsurface expression, with a proportion being intracellular,
whereas the T50M is almost completely retained in the
cytoplasm. Based on the pattern of S59P expression, we
might suggest that this novel mutation, similarly to R92Q
and differently from T50M, does not promote intracellular
retention of TNF-R1.
We then verified whether the exposure of cells to the
TNF-R1 cognate ligand TNF exerts a mutation-dependent
effect on receptor expression. In WT, S59P and R92Q
mutant cells, TNF caused an enforced expression of the
Greco et al. Arthritis Research & Therapy  (2015) 17:93 Page 12 of 15TNF-R1 mainly in the cytosol but also at the cell mem-
brane, while in T50M mutant cells TNF induced an
enforced expression of cytoplasmic aggregates. It might be
suggested that S59P, similarly to the R92Q mutation, does
not alter TNF-R1 trafficking from the cytoplasm to the
surface membrane, while the T50M mutation causes a
misfolded protein that overloads, leading to the formation
of aggregates in the cytosol [32,45].
The pivotal role of an altered TNF receptor in TRAPS
pathophysiology supports traditional therapy with eta-
nercept, a fusion molecule of TNF-R2/FcIg [21,25,36], or
with other anti-TNF agents such as infliximab, a monoclo-
nal anti-TNF antibody; however, in most cases these ther-
apies were shown to be only partially efficacious [46,47].
Therapy with anakinra, a recombinant interleukin-1 re-
ceptor antagonist, has recently proven to be a promising
therapeutic alternative, preventing short-term disease re-
lapse even in etanercept-resistant patients [33,48-50]. The
success of this therapeutic approach, also recorded in our
S59P TRAPS patient, might be due to increased IL-1β
secretion for impaired autophagy [51], but also to the in-
teractions occurring between IL-1 and TNF-R1 signaling
[52]. TNF-R1 trimerizes before binding to TNF trimer,
which induces TRADD-dependent and independent acti-
vation of several downstream signaling pathways, includ-
ing the NF-κB, apoptosis, JNK, c-Jun, p38-MAPK and
ERK [53]. IL-1β signaling is initiated with recruitment of
MyD88 to the Toll-IL-1 receptor domain, followed by the
phosphorylation of several kinases and activation of the
NF-κB signaling pathway [49].
By studying all the above TNF-R1 signaling pathways
and the IL-1 pathway in WT and mutant cells with a
comprehensive RPPA approach, we demonstrated that in
the presence of T50M, not S59P or R92Q mutations,
TNF-R1, NF-κB and caspase 1 are constitutively activated.
In agreement with the hypothesis that a possible associ-
ation between TNF-R1 mutation and IL-1 signaling exists,
constitutively activated IRAK and TAK proteins, involved
in the IL-1 signaling pathway, were observed in cells carry-
ing the S59P mutation. In R92Q cells we observed an at-
tenuation of NF-κB, c-Jun, ERK, Akt, and inflammasome
pathways and an increase in suppressor of cytokine signal-
ing (SOCS) protein 3, which attenuates the intensity and/
or duration of a cell’s response to a diverse range of extra-
cellular stimuli by suppressing the signal transduction pro-
cesses. These findings indicate that any TNFRSF1A mutant
differently affects the pro-inflammatory signaling pathways
downstream of TNF-R1: the T50M mutant activates TNF-
R1 pro-inflammatory signaling pathways, the novel identi-
fied S59P mutant activates IL-1 signaling and the R92Q
mutant inhibits, not activates, TRADD-dependent sig-
naling. A common feature of all studied TNFRSF1A mu-
tants was the constitutive inhibition of apoptosis by
increased inhibition of BCL-2 and BAD. Consideringthat the molecular pathogenetic mechanisms proposed
for TRAPS include defective autophagy, ROS produc-
tion, defective apoptosis and enhanced activation of NF-
κB, our results suggest that a defective apoptosis is a
common feature of different TNFRSF1A mutations, and
that their differences in causing more or less severe
forms of disease are probably related to their ability in
sustaining ligand-dependent and independent NF-κB acti-
vation and inflammation.
For this reason the NF-κB pathway was studied in
more detail in our experimental setting. The activated
TNF receptor triggers a set of cascade events, including
IKK complex activation, phosphorylation and IκB-α deg-
radation, and activation and nuclear translocation of the
NF-κB complex that in turn modulates the expression of
a sequence of pro-inflammatory genes [10-17,26]. By
RPPA analysis, NF-κB was shown to be activated both
constitutively and after exposure to TNF and IL-1β in
the T50M mutant. Western blot analysis confirmed that
TNF and IL-1β induced the phosphorylation of IκB-α,
which was higher and more persistent in T50M and S59P
than in the WT TNFRSF1A cells. This phenomenon could
be explained by the combined TNF-independent autoacti-
vation of the mutated receptor and by the TNF-dependent
activation of the WT receptor, since both receptors are
present in these heterozygous cells. The IκB-α down-
stream signaling involves the p65 subunit, which plays an
important role in protecting from apoptosis and innate
immunity [13,54]. Confirming reports by Yousaf et al. on
T50K [30] and of Churchman et al. on T50M [55], we
found that the p65 subunit was constitutively active in the
T50M TNFRSF1A cells and, using Western blot analysis
(see Figure 4), we found that TNF induced a higher phos-
phorylation of the nuclear p65 subunit in the mutated ra-
ther than the WT TNFRSF1A cells. The constitutive and
stimulus-dependent accumulation of p65 in the nucleus
might confer insensitivity to apoptosis and keep the cells
in a hyper-inflammatory state. Findings in an in vitro
model correlated with results obtained from the PBMCs
of TRAPS patients. The NF-κB pathway was constitutively
activated and upregulated by inflammatory stimuli in
the presence of TRAPS-associated mutations. IL-1β sup-
ported the significance of IκB-α phosphorylation and
NF-κB activation in S59P TRAPS PBMCs.
NF-κB activation leads to pro-inflammatory cytokine
secretion [11,13,14]. We investigated this phenomenon
by measuring IL-8 in transfected cells and IL-8, IL-6,
TNF and IL-1β in PBMCs from the S59P and R92Q
TRAPS patients. A limitation of our study is that there
was no patient with the T50M mutation because it was
never found in our series of TRAPS patients, and this
prevents from comparing accurately the results obtained
with the other variants. TNF induced a significant in-
creased release of IL-8 in R92Q and in S59P TNFRSF1A
Greco et al. Arthritis Research & Therapy  (2015) 17:93 Page 13 of 15cells. This finding is in agreement with results described
by Nedjai et al. [35] and was supported by the clinical
data: IL-1β induced a significantly higher and persistent
IL-6 and IL-8 secretion in the S59P TRAPS PBMCs and
IL-6 secretion in the R92Q TRAPS PBMCs, which were
maintained in long-term culture (up to 72 hours) in order
to exclude any interference as a consequence of therapy.
IL-8 response to TNF stimulation of T50M cells was
similar to WT cells in agreement with findings from
Churchman et al. [55], who found that the PBMCs car-
rying the T50M or C88R mutation, despite having ele-
vated basal p65 nuclear expression, did not show further
increase in p65 or p50 NF-κB subunits following stimu-
lation with TNF. This relative low sensitivity of T50M
mutant cells to TNF might be due to the low membranal
expression of TNF-R1, as previously shown by flow cyto-
metric FACS analysis [55] and confirmed in the present
study by immunofluorescence (see Figure 1). However,
our findings are in disagreement with those from Nedjai
et al. [35], who studied the T50K mutation. This sup-
ports the notion that the molecular structure of the re-
placement amino acid (Methionine-M not Lysine-K),
although involving the same tyrosine residue at position
79 in the mature protein, might differently affect recep-
tor function.
In view of these considerations, we performed the same
experiments using IL-1β stimulation. In a physiological
state, IL-1β did not apparently influence NF-κB activity in
the cell line considered. Instead, in the TNFRSF1A mu-
tated cells, this cytokine induced an inflammatory re-
sponse. The IL-1R pathway proceeded in canonical NF-κB
pathway. We suggest that IL-1b enhances the inflamma-
tory response of TNRSF1A mutated cells due to their
hyper-inflammatory background.Conclusions
We identified and functionally characterized a new (S59P)
TNFRSF1A mutation. This mutation is associated with a
TRAPS phenotype characterized by a high degree of in-
flammation only partially responsive to steroid treatment.
This phenotype appeared to be highly responsive to ana-
kinra, which was used in the patient in question over
the course of one year. The S59P mutation determines a
constitutive activation of the IL-1R pathway, inhibition
of apoptosis, and an enhanced and persistent NF-κB
activation and cytokines secretion in response to IL-1β
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